Robert G. Maki, MD, PhD, FACP, FASCO, discusses the utility of IDH1/2 inhibitors in chondrosarcoma.
Robert G. Maki, MD, PhD, FACP, FASCO, clinical director, Sarcoma Program, Abramson Cancer Center, Penn Medicine, discusses the utility of IDH1/2 inhibitors in chondrosarcoma.
The potential advantage of metabolic therapy among patients with cancer has garnered significant research interest, says Maki.
IDH1/2 inhibitors, for example, are available to patients with gliomas and leukemias. Additionally, patients with chondrosarcoma, a rare subtype of sarcoma, frequently harbor IDH1/2 mutations.
Although IDH1/2 alterations may not be driver mutations, IDH1 inhibitors have demonstrated prolonged stability of disease with potential tumor shrinkage in patients with chondrosarcoma, says Maki.
Studies evaluating IDH1/2 inhibitors in this setting are in early phases, but these data suggest that metabolic therapy may be an effective approach in treating patients with chondrosarcoma in the future, concludes Maki.